Company Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization.
NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
| Country | United States |
| Founded | 2001 |
| IPO Date | Nov 2, 1999 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,100 |
| CEO | Christopher Smith |
Contact Details
Address: 9490 NeoGenomics Way Fort Myers, Florida 33912 United States | |
| Phone | 239 768 0600 |
| Website | neogenomics.com |
Stock Details
| Ticker Symbol | NEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001077183 |
| CUSIP Number | 64049M209 |
| ISIN Number | US64049M2098 |
| Employer ID | 74-2897368 |
| SIC Code | 8734 |
Key Executives
| Name | Position |
|---|---|
| Christopher Michael Smith BSc | Chief Executive Officer and Director |
| Jeffrey S. Sherman M.B.A. | Chief Financial Officer |
| Vishal Sikri | President of Advanced Diagnostics |
| Melody Harris Esq., J.D. | President and Chief Operating Officer of Informatics |
| Warren Stone | Chief Commercial Officer |
| Gregory D. Aunan | Chief Accounting Officer |
| Kendra Sweeney | Vice President of Investor Relations and Communications |
| Alicia Olivo | Executive Vice President of Business Development, General Counsel and Corporate Secretary |
| Hutan Hashemi J.D. | Chief Compliance Officer |
| Dr. Derek Lyle M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 144 | Filing |
| Aug 15, 2024 | 144 | Filing |
| Jul 30, 2024 | 10-Q | Quarterly Report |
| Jul 29, 2024 | 8-K | Current Report |
| Jun 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |